A randomized, Investigator-and patient-blind, placebo-controlled, parallel group first in human and proof of concept study to evaluate the safety, tolerability, and efficacy of CLL442 in patients with Cutaneous Squamous Cell Carcinoma in situ (SCCis) - Not applicable